Welcome to our dedicated page for Femasys news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on Femasys stock.
Femasys Inc. (NASDAQ: FEMY) is a leading biomedical company dedicated to transforming women's healthcare through innovative solutions. The company focuses on developing and providing minimally invasive, non-surgical products that are accessible in-office, thus improving patient care and overall health economics. Femasys' mission addresses severely underserved areas in women's health, aiming to make a significant clinical impact worldwide.
The company's recent achievements include the FDA clearance and commercial launch of FemaSeed® Intratubal Insemination, a novel infertility treatment that enhances fertilization by delivering sperm directly to the fallopian tube. This product offers a cost-effective and less invasive alternative to traditional infertility treatments like IVF and ICSI. FemaSeed has demonstrated promising results, with a 24% pregnancy rate in severe male factor infertility cases.
Femasys is also advancing the development of FemBloc®, a non-surgical, in-office permanent birth control method currently in late-stage clinical trials. This product aims to provide a safer and more affordable option compared to long-standing surgical alternatives.
The company's diagnostic product portfolio includes FemVue® for fallopian tube assessment, FemCath® for selective fallopian tube evaluation, and FemCerv® for cervical cancer diagnosis. These products have achieved regulatory approvals in the U.S., Canada, and other international markets, and are ready for commercial deployment.
Femasys prides itself on its experienced management team, boasting over 200 years of collective industry expertise, and the guidance of world-class medical advisors. All products developed by Femasys adhere to stringent FDA regulations and ISO 13485 standards, ensuring the highest quality and compliance.
Recent news highlights include the first commercial procedure using FemaSeed, the release of promising topline data from pivotal trials, and significant capital infusion to support commercial initiatives into the second half of 2025. The company's strategic focus remains on the commercialization of its infertility and diagnostic product portfolios, ongoing pivotal trials, and addressing the critical unmet needs in women's healthcare.
Femasys Inc. (NASDAQ: FEMY) announced that CEO Kathy Lee-Sepsick will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting at 7:00 AM ET on September 12.
The conference will feature a fireside chat format, and Femasys management will hold one-on-one meetings during the event. Femasys focuses on developing minimally invasive technologies for reproductive health, including FemBloc® for birth control and FemaSeed® for infertility.
Femasys Inc. (NASDAQ: FEMY) reported its financial results for Q2 and the first half of 2022, highlighting important advancements in women's reproductive health technologies. Revenue for the six months decreased by 4.8% to $624,518, with R&D expenses rising significantly by 53.1% to $2.9 million due to increased clinical costs. The net loss grew to $5.5 million, or $0.47 per share. Upcoming product launches, including FemCerv® and FemCath™, are expected by year-end. Enrollment for the FemBloc® study is on track, with an interim analysis for FemaSeed® due in Q4.
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's health, will hold one-on-one virtual meetings during the BTIG Biotechnology Conference on August 8-9, 2022, at the St. Regis New York Hotel. The company develops minimally invasive technologies for reproductive health, including its lead products, FemBloc® for permanent birth control and FemaSeed® for infertility. Interested participants are encouraged to contact their BTIG representative for scheduling.
Femasys Inc. (NASDAQ: FEMY) will host a significant webinar on July 28, 2022, at 10:30 AM EDT, featuring Dr. Paul D. Blumenthal, who will discuss the company's innovative FemBloc solution for permanent birth control. This event comes in response to the reversal of Roe v. Wade, emphasizing the unmet needs for permanent contraceptive options. FemBloc utilizes a unique delivery method that safely closes the fallopian tubes without surgery, aiming for confirmation of success within 90 days. A live Q&A session will follow the presentation.
Femasys Inc. (NASDAQ: FEMY) has been invited to present at the Women’s Health Panel Discussion hosted by Maxim Group LLC on July 13, 2022, at 11:00 a.m. ET. Kathy Lee-Sepsick, CEO, will discuss the implications of the Supreme Court's decision to overturn Roe v. Wade on women's health and contraception. This virtual event will spotlight the critical issues in women's reproductive health, bringing together key industry players. Femasys is known for its innovations in minimally invasive reproductive health technologies, including FemBloc and FemaSeed.
Femasys Inc. (NASDAQ: FEMY) announced the appointment of Charles Larsen as the new non-executive Chair of the Board, succeeding founder Kathy Lee-Sepsick. With over 40 years in the medical device industry, Larsen is expected to enhance corporate governance and aid Femasys in advancing its product candidates like FemBloc and FemaSeed. Kathy Lee-Sepsick emphasized Larsen's leadership experience and insight in strategic transformations as vital for the company's mission to improve women's health globally.
Femasys Inc. (NASDAQ: FEMY) announced that its CEO, Kathy Lee-Sepsick, will present at the LSX World Congress USA in Boston from June 21-22, 2022. She will lead a session on overcoming regulatory hurdles for women’s health products, focusing on FemaSeed and FemBloc. The Women’s Health CEO Forum will also feature her insights on industry collaboration. This event gathers leaders in biotech and medtech to drive innovation and growth in women's reproductive health.
Femasys Inc. (NASDAQ: FEMY) announced Q1 2022 financial results, reporting a net loss of $2.88 million or $0.24 per share. General and administrative expenses rose by 62.3% to $1.45 million, and R&D expenses increased by 42.8% to $1.42 million. Sales of FemVue® decreased by 2.5% to $321,405. Despite these challenges, Femasys is set to commercialize FemCerv® and FemCath™ by year-end and is making progress in clinical trials for FemBloc and FemaSeed. The company aims to enhance women's health solutions with its expanding product portfolio.
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on women's reproductive health, will participate in the 2022 Virtual Growth Conference from March 28-30. CEO Kathy Lee-Sepsick will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 from 3:00 pm to 4:30 pm ET. The conference will discuss innovations in women's health, highlighting Femasys's ongoing development of minimally invasive technologies, including FemBloc® and FemaSeed® for permanent birth control and infertility treatment respectively. For more details, registration is available online.
Femasys Inc. (NASDAQ: FEMY) reported its 2021 financial results, showcasing a revenue increase of 13.7% to $1.18 million from FemVue® sales. R&D expenses slightly decreased by 1.1% to $4.08 million, while G&A expenses surged by 67.5% to $4.26 million due to increased professional costs. The net loss was $7.54 million, equating to $1.12 per share, a rise from the previous year's loss of $6.91 million. The company anticipates significant clinical advancements, including the upcoming launch of FemCerv® and completion of the FemBloc study enrollment.
FAQ
What is the current stock price of Femasys (FEMY)?
What is the market cap of Femasys (FEMY)?
What is Femasys Inc. known for?
What is FemaSeed?
What are the recent achievements of Femasys?
What is FemBloc?
What diagnostic products does Femasys offer?
How does Femasys ensure product quality?
What markets has Femasys achieved regulatory approvals in?
Who leads Femasys Inc.?
What are the financial prospects for Femasys?
Where can I learn more about Femasys' products and updates?
